US-based digital health company Profusa, Inc. (NASDAQ: PFSA), which develops tissue-integrated biosensors for continuous biochemical monitoring, said on Wednesday that it has signed a distributor partnership with French medical device commercialisation company MedSell to market Lumee Oxygen tissue monitoring in France.

The product will be sold into hospital and outpatient settings, including wound care and healing clinics treating complex and chronic wounds.

Building on Profusa's existing distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom and Scandinavia, this latest agreement extends its European reach to more than 200,000 annual critical limb ischaemia cases in the European Union. The MedSell partnership also complements Profusa's collaboration with the Vascular Center at Groupe Hospitalier Paris Saint Joseph in Paris, where Lumee Oxygen is used in clinical practice and studies, including home monitoring applications, and accounts for around 8% of all critical limb threatening ischaemia cases in France.

Profusa expects to begin commercialisation in Europe in the second quarter of 2026, with potential revenue of USD0.5m to USD2m in 2026 and USD9m to USD13m in 2027, and is targeting USD200m to USD250m in revenue by 2030.